Zontivity vorapaxar: Additional Phase III data

Additional data from 3,623 patients with diabetes mellitus and a prior MI and without a history of stroke or transient ischemic attack in the double-blind Phase III TRA 2P-TIMI 50 trial showed that Zontivity vorapaxar plus standard of care (SOC)

Read the full 404 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE